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A B S T R A C T
Background
Maintenance treatment with long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) can relieve asthma symptoms and
reduce the frequency of exacerbations, but there are limited treatment options for people who do not gain control on combination
LABA/ICS. Long-acting muscarinic antagonists (LAMA) are a class of inhaled drug which have been effective for people with chronic
obstructive pulmonary disease and are now becoming available for people with asthma to take alongside their LABA/ICS inhaler.
Objectives
To assess the effects of adding a long-acting muscarinic antagonist (LAMA) to combination long-acting beta2-agonists (LABA) and
inhaled corticosteroids (ICS) in adults whose asthma is not well controlled by LABA/ICS.
Search methods
We identified trials from the Cochrane Airways Review Group Specialised Register (CAGR) up to January 2016. We also searched
ClinicalTrials.gov, theWHO trials portal, and reference lists of other reviews, and we contacted trial authors for additional information.
Selection criteria
We included parallel randomised controlled trials (RCTs) of at least 12 weeks’ duration. Studies met the inclusion criteria if they
compared LAMA as an add-on to LABA/ICS versus LABA/ICS alone for adults with asthma. We included studies reported as full text,
those published as abstract only, and unpublished data. Primary outcomes were exacerbations requiring oral corticosteroids (OCS),
validated measures of asthma control, and serious adverse events (including mortality).
Data collection and analysis
Two review authors screened searches and independently extracted details on risk of bias and numerical data. We analysed dichotomous
data as odds ratios (ORs) and continuous data as mean differences (MD) using a random-effects model. We rated all outcomes using
GRADE.
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Main results
We found four double-blind, double-dummy trials comparing LAMA to placebo, including 1197 people with asthma taking combi-
nation LABA/ICS. One of the trials was designed to study glycopyrronium bromide but was withdrawn prior to enrolment, and the
other three all studied tiotropium bromide (mostly 5 µg once daily via Respimat) over 48 to 52 weeks. People in the trials had a mean
forced expiratory volume in one second (FEV1) of 55% of their predicted value, indicating severe asthma.
People randomised to take tiotropium add-on had fewer exacerbations requiring oral corticosteroids than those continuing to take
LABA/ICS alone, but the confidence intervals did not rule out no difference (OR0.76, 95%CI 0.57 to 1.02;moderate quality evidence).
Over 48 weeks, 328 out of 1000 people taking their usual LABA/ICS would have to take oral corticosteroids for an exacerbation
compared with 271 if they took tiotropium as well (95% CI 218 to 333 per 1000). Analyses comparing the number of exacerbations
per patient in each group (rate ratio) and the time until first exacerbation (hazard ratio) were in keeping with the main result. Quality
of life, as measured by the Asthma Quality of Life Questionnaire (AQLQ) was no better for those taking tiotropium add-on than for
those taking LABA/ICS alone when considered in light of the 0.5 minimal clinically important difference on the scale (MD 0.09,
95% CI − 0.03 to 0.20), and evidence for whether tiotropium increased or decreased serious adverse events in this population was
inconsistent (OR 0.60, 95% CI 0.24 to 1.47; I2 = 76%).
Within the secondary outcomes, exacerbations requiring hospital admission were too rare to tell whether tiotropium was beneficial over
LABA/ICS alone. There was high quality evidence showing benefits to lung function (trough FEV1 and forced vital capacity (FVC))
and potentially small benefits to asthma control. People taking tiotropium add-on were less likely to experience non-serious adverse
events.
Authors’ conclusions
Tiotropium add-on may have additional benefits over LABA/ICS alone in reducing the need for rescue oral steroids in people with
severe asthma. The effect was imprecise, and there was no evidence for other LAMA preparations. Possible benefits on quality of life
were negligible, and evidence for the effect on serious adverse events was inconsistent. There are likely to be small added benefits for
tiotropium Respimat 5 µg daily on lung function and asthma control over LABA/ICS alone and fewer non-serious adverse events. The
benefit of tiotropium add-on on the frequency of hospital admission is still unknown, despite year-long trials.
Ongoing and future trials should clearly describe participants’ background medications to help clinicians judge how the findings relate
to stepwise care. If studies test LAMAs other than tiotropium Respimat for asthma, they should be at least six months long and use
accepted and validated outcomes to allow comparisons of the safety and effectiveness between different preparations.
P L A I N L A N G U A G E S U M M A R Y
Does adding tiotropium, a long-acting muscarinic antagonist (LAMA), to combination therapy (LABA/ICS) help to control
asthma?
Adding the LAMA tiotropium Respimat inhaler to combination LABA/ICS inhaler may reduce the need for rescue oral steroids. A
noticeable benefit on quality of life is unlikely, and we couldn’t tell if it reduced hospital admissions, but adding tiotropium has some
benefit on lung function, asthma control, and non-serious side effects.
More detail about the studies and results:
Taking a daily inhaler containing a long-acting beta2-agonist and an inhaled corticosteroid (LABA/ICS) can improve symptoms and
reduce the likelihood of asthma attacks. If this doesn’t help, another type of inhaled drug called a long-acting muscarinic antagonist
(LAMA), which has been effective for people with other breathing conditions, is now available for people with asthma to take as well
as their LABA/ICS inhaler.
We wanted to find out whether adding a LAMA to LABA/ICS is better than continuing LABA/ICS alone for adults with asthma.
We found four relevant studies, but one was withdrawn before anyone was signed up. The other three compared a LAMA called
tiotropium Respimat to placebo for around a year, with participants in both groups continuing to take their usual LABA/ICS inhaler.
People generally had quite poor lung function when they entered the studies, suggesting their asthma was not well controlled - in
respiratory medicine, this is known as ’severe asthma’.
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Over 48 weeks, 328 out of 1000 people taking their usual LABA/ICS had to take a course of oral steroids compared with 271 if they
took tiotropium as well. However, uncertainty in the results meant that rather than there being 271 people taking oral steroids, there
could be anywhere from 218 to 333 people per 1000 who would have to take oral steroids, so we couldn’t be sure of the benefit. Quality
of life scores were not that different between those who took tiotropium and those who didn’t. The studies showed different results for
whether people taking tiotropium were more likely to suffer a serious side effect, but fewer people had non-serious side effects if they
took tiotropium.
We couldn’t tell whether taking tiotropium on top of LABA/ICS reduced the number of people who had to go to hospital for an asthma
attack because it didn’t happen often enough for us to have confidence in the result. There was high quality evidence that showed
benefits to lung function and probably small benefits on measures of asthma control.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
LAM A versus placebo in adults with asthma taking background LABA/ ICS
Patient or population: adults with asthma
Setting: outpat ient
Intervention: LAMA + background LABA/ ICS
Comparison: LABA/ ICS alone
The studies randomised part icipants to LAMA or placebo and required part icipants to be taking background LABA/ ICS
The durat ions shown are the weighted means of the studies included in each analysis
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with LABA/ ICS Risk with LAM A +
LABA/ ICS
Exacerbations requir-
ing oral corticosteroids
48 weeks
328 per 1000 271 per 1000
(218 to 333)
OR 0.76
(0.57 to 1.02)
907
(2 RCTs)
⊕⊕⊕©
Moderate1
Analyses comparing
the number of exacer-
bat ions per pat ient in
each group (rate ra-
t io) and the t ime until
f irst exacerbat ion (haz-
ard rat io) were in keep-
ing with the main result
Quality of life (AQLQ)
7-point scale f rom 1 to
7
Higher scores are bet-
ter
48 weeks
The mean AQLQ was 5.
03
The mean AQLQ score
in the LAMA group was
0.09 better
(0.03 better to 0.20
worse)
- 907
(2 RCTs)
⊕⊕⊕⊕
High2
No benef it of LAMA
add-on over LABA/ ICS
alone. The MCID for the
AQLQ is 0.5
Serious adverse events
49 weeks
96 per 1000 60 per 1000
(25 to 134)
OR 0.60
(0.24 to 1.47)
1197
(3 RCTs)
⊕⊕©©
Low3,4
Evidence does not sug-
gest LAMA increases
adverse events.
Post hoc sensit ivity
analysis removing Ohta
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2014 gave a more pre-
cise est imate but did
not change the conclu-
sions
Exacerbations requir-
ing hospital admission
49 weeks
43 per 1000 30 per 1000
(15 to 59)
OR 0.68
(0.34 to 1.38)
1191
(3 RCTs)
⊕⊕©©
Low5,6
Too few events to de-
tect whether there is a
benef it of LAMA add-on
Lung function (change
in trough FEV1 L)
49 weeks
The mean change in
trough FEV1 was 0.08 L
The mean change in
trough FEV1 (L) in the
intervent ion group was
0.07 higher
(0.03 higher to 0.11
higher)
- 1191
(3 RCTs)
⊕⊕⊕⊕
High7
Some benef it of LAMA
add-on over LABA/ ICS
alone
Asthma control (ACQ)
7-point scale f rom 0 to
6
Lower scores are better
48 weeks
The mean asthma con-
trol (ACQ) was 2.13
The mean asthma con-
trol (ACQ) in the inter-
vent ion group was 0.13
better
(0.23 better to 0.02 bet-
ter)
- 907
(2 RCTs)
⊕⊕⊕⊕
High
Scores with LAMA add-
on were better than
LABA/ ICS alone, but the
dif ference was not clin-
ically signif icant (MCID
= 0.5)
Any adverse events
49 weeks
813 per 1000 753 per 1000
(693 to 803)
OR 0.70
(0.52 to 0.94)
1197
(3 RCTs)
⊕⊕⊕⊕
High7
The listed events were
reported in at least 2%
of pat ients who under-
went randomisat ion
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI). For the cont inuous outcomes, we calculated a weighted mean of the scores in the control groups.
ACQ: Asthma Control Quest ionnaire; AQLQ: Asthma Quality of Life Quest ionnaire; CI: conf idence interval; FEV1 : f orced expiratory volume in one second; LABA/ ICS: combined
long-act ing beta2-agonist and inhaled cort icosteroid; LAM A: long-act ing muscarinic antagonist ; M CID: m inimal clinically important dif f erence; OR: odds rat io; RCT : randomised
controlled trial.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
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Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Less than 300 events in the analysis. The conf idence intervals included an important benef it of LAMA add-on and no
dif ference (− 1 imprecision).
2 Both conf idence intervals were within the 0.5 minimal clinically important dif f erence for the scale. The ef fect suggests no
important dif f erence between the treatments (no downgrade).
3 I2 = 76%, P = 0.02. Ohta 2014 showed signif icant ly fewer serious adverse events on LAMA while the other two trials did not
show a dif ference against LABA/ ICS alone (− 1 inconsistency).
4 The conf idence intervals included appreciable harm on either treatment, largely because Ohta 2014 had a much larger ef fect
in favour of LAMA. Ohta 2014 was dif ferent f rom the other two studies because it had two dose groups that were combined in
the analysis. In addit ion, the study included part icipants who were taking either ICS alone as background treatment or LABA/
ICS. As such, some results are f rom part icipants who do not meet all inclusion criteria for this review. A post hoc sensit ivity
analysis removing this study made the ef fect much more precise (− 1 indirectness, no downgrade for imprecision).
5 Ohta 2014 showed a much larger ef fect in favour of LAMA add-on than the other two studies, which may be due to the
indirectness of the populat ion (− 1 indirectness). However, the Ohta 2014 ef fect was based on far fewer events so carried
less weight and the conf idence intervals included the ef fects of the other two studies (no downgrade for inconsistency).
6Removing Ohta 2014 in a post hoc sensit ivity analysis on the basis of an indirect populat ion did not signif icant ly improve the
precision of the est imate (− 1 imprecision).
7The study with an indirect populat ion contributed to this outcome but its results were not inconsistent with the other studies
(no downgrade for indirectness).
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B A C K G R O U N D
Description of the condition
Asthma is a “common chronic non-communicable disease that
affects as many as 334 million people of all ages in all parts of
the world” (Global Asthma Report 2011). It is the 14th most im-
portant disorder in terms of the extent and duration of disability,
not only because of recurring physical symptoms like wheezing,
shortness of breath, chest tightness, and cough, but also because
of associated psychological and social effects (GINA 2014; Global
Asthma Report 2011). Symptoms are caused by chronic inflam-
mation of the airways, which are hyperresponsive to various risk
factors (e.g. allergens, tobacco, infection), leading to narrowing of
the airways and mucus production (GINA 2014). Much of the
burden is felt in low- and middle-income countries, where treat-
ment costs lead to uncontrolled symptoms and exacerbations, but
studies report avoidable morbidity and mortality worldwide as the
result of inappropriate or insufficient management of the disease
(Global Asthma Report 2011; NRAD 2014).
Treatment recommended by internationally recognised guidelines
follows a stepwise approach tomaintain symptom control, prevent
exacerbations and minimise drug costs and side effects (e.g. BTS/
SIGN 2014; GINA 2014). Regular clinic visits, self monitoring
and an asthma action plan are important if patients are to receive
treatment consistent with their level of asthma control, which
is commonly assessed by frequency and severity of symptoms,
limitation of daily activities, rescue inhaler use, and lung function
(GINA 2014; NRAD 2014).
Description of the intervention
Many people with asthma take daily controller medication to
“prevent symptoms, improve lung function, and prevent attacks”
(GINA 2014), and as an as-needed reliever inhaler for quick relief
of symptoms. Inhaled corticosteroids (ICS) are an effective con-
troller medication for asthma and are the preferred initial con-
troller choice when people require regular daily therapy (Adams
2008a; Adams 2008b; GINA 2014). If low-dose inhaled corticos-
teroids are ineffective, they can be combined with a long-acting
beta2-agonist (LABA) in stepwise management (Ducharme 2008;
Ducharme 2010). Limited step-up options are available for pa-
tients who continue to have frequent symptoms and exacerbations
while taking combination LABA/ICS, but data are emerging to
support the use of long-actingmuscarinic antagonist (LAMA) add-
on therapy for this group of patients (Lipworth 2014), and the li-
cence for one LAMAhas recently been extended for this indication
(eMC 2014). The licence extension applies only to tiotropium de-
livered via the Respimat device - not to tiotropium via the Handi-
Haler device nor to other available LAMAs such as aclidinium and
glycopyrronium. LAMAs are not yet available in a single inhaler
with LABA/ICS, so patients taking these three types of medica-
tions have to take LABA/ICS in a single inhaler and LAMA in
another. Twice daily preparations of combination LABA/ICS are
common (salmeterol/fluticasone propionate or formoterol/budes-
onide), but once-daily preparations are emerging (vilanterol/fluti-
casone furoate), and LAMA are taken once daily.
How the intervention might work
LAMAs ease muscle contraction and mucus secretion by block-
ing acetylcholine receptors on airway smooth muscle, glands, and
nerves (Moulton 2011). Used as triple therapy (i.e. LAMA/LABA/
ICS), studies have also suggested that combining a LABA and a
LAMAmay lead to additional bronchodilation through the inter-
action of their different mechanisms, although this theory requires
further study (Kerstjens 2012). For patients with poorly controlled
asthma, treatment guidelines recommend that the ICS compo-
nent within the LABA/ICS combination be increased rather than
adding on other therapies, as there is limited evidence of benefit
from the addition of other therapeutic classes such as leukotriene
antagonists and methylxanthines (GINA 2014). The addition of a
LAMA for added long-acting bronchodilation may provide an al-
ternative option, allowing doses of steroids to be minimised to re-
duce the risk of side effects (Fardon 2007). Inhaled corticosteroids
have been associated with dose-related systemic side effects such
as hypothalamo-pituitary adrenal (HPA) axis suppression, reduc-
tion in bone density, cataracts, and skin bruising (Lipworth 1999;
Pandya 2014). LAMAs are associated with their own side effects,
which include dry mouth, metallic taste, mydriasis, and urinary
retention (Therapeutic Choices 2014).
Why it is important to do this review
Now that one preparation of LAMA has been licensed for asthma
(eMC 2014), it is important for researchers to critically assess
the evidence base for its use in the clinical scenario for which it
is indicated. Limited treatment options are available for patients
whose asthma does not respond well to LABA/ICS, so there is a
need to fully assess the efficacy and safety of potential therapies to
improve the quality of life of this group of patients.
O B J E C T I V E S
To assess the effects of adding a long-acting muscarinic antagonist
(LAMA) to combination long-acting beta2-agonists (LABA) and
inhaled corticosteroids (ICS) in adults whose asthma is not well
controlled by LABA/ICS.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We included parallel and cross-over randomised controlled trials
(RCTs) of at least 12weeks’ duration.We included studies reported
as full text, those published as abstract only and unpublished data.
We did not exclude studies on the basis of blinding.
Types of participants
We included studies in adults (aged 18 years or older) with
asthma who were taking LABA/ICS combination therapy. We ex-
cluded trials that included participants with other chronic respi-
ratory comorbidities (e.g. chronic obstructive pulmonary disease,
bronchiectasis).
If studies included adults and adolescents or children younger than
age 12 and data were not reported separately, we included them if
the mean age in both groups was over 18 years.
Types of interventions
We included trials assessing a LAMA add-on to any dose of LABA/
ICS combination therapy versus the same dose of LABA/ICS
alone.We included studies comparing LAMAwith placebo if they
required participants to be taking LABA/ICS combination ther-
apy for inclusion in the trial, and if the dose taken was equivalent
in intervention and comparison groups.
We included studies involving the addition of the followingLAMA
at any dose.
1. Tiotropium (Spiriva Handihaler or Respimat).
2. Aclidinium bromide (Eklira Genuair).
3. Glycopyrronium bromide (Seebri Breezhaler).
We included studies that allowed participants to continue us-
ing additional short- or long-acting medications (e.g. salbutamol,
terbutaline and ipratropium, leukotriene receptor antagonists),
provided they were not part of the randomised treatment.
Types of outcome measures
Primary outcomes
1. Exacerbations requiring oral corticosteroids
2. Quality of life (measured on a validated asthma scale, e.g.
Asthma Quality of Life Questionnaire, AQLQ)
3. Serious adverse events (all causes)
Secondary outcomes
1. Exacerbations requiring hospital admission
2. Lung function (preferably trough forced expiratory volume
in one second, or FEV1)
3. Asthma control (measured on a validated scale, e.g. Asthma
Control Questionnaire (ACQ), Asthma Control Test)
4. Any adverse events
Reporting in the trial of one of more of the outcomes listed here
was not an inclusion criterion for the review.
If trials reported exacerbations as a composite of more than one
definition (e.g. patients with one or more exacerbations requiring
hospitalisation or visit to the emergency department), we analysed
them separately.
Search methods for identification of studies
Electronic searches
We identified trials from the Cochrane Airways Group Specialised
Register (CAGR), which is maintained by the Trials SearchCo-or-
dinator for theGroup. The register contains trial reports identified
through systematic searches of bibliographic databases, including
the Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, EMBASE, the Cumulative Index to Nursing and Al-
lied Health Literature (CINAHL), the Allied and Complemen-
taryMedicineDatabase (AMED) and PsycINFO.TheCAGRalso
includes records identified by handsearching respiratory journals
and meeting abstracts (please see Appendix 1 for further details).
We searched all records in the CAGR using the search strategy
presented in Appendix 2.
We also conducted a search of www.ClinicalTrials.gov and the
World Health Organization (WHO) trials portal (www.who.int/
ictrp/en/) using search terms adapted from the strategy in
Appendix 2. We searched all databases from their inception to
January 2016 and we imposed no restriction on language of pub-
lication.
Searching other resources
We checked the reference lists of all primary studies and review
articles for additional references. We searched relevant manufac-
turers’ websites for trial information.
We searched for errata or retractions published in full text on
PubMed (www.ncbi.nlm.nih.gov/pubmed) for included studies in
August 2015.
Data collection and analysis
Selection of studies
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Two review authors (KMK and KD) independently screened titles
and abstracts for inclusion of all potential studies identified as a
result of the search and coded them as ’retrieve’ (eligible or poten-
tially eligible/unclear) or ’do not retrieve’. We retrieved the full-
text study reports/publications; two review authors (KMK and
KD) independently screened the full text, identified studies for
inclusion and identified and recorded reasons for exclusion of inel-
igible studies. We resolved disagreements through discussion. We
identified and excluded duplicates and collatedmultiple reports of
the same study, so that each study rather than each report was the
unit of interest in the review. We recorded the selection process
in sufficient detail to complete a Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) flow diagram
and a ’Characteristics of excluded studies’ table (Moher 2009).
Data extraction and management
Weused a data collection form that had been piloted on at least one
study in the review to document study characteristics and outcome
data. One review author (KMK) extracted the following study
characteristics from included studies, and a second review author
(KD) spot-checked them for accuracy against the trial reports.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and locations, study
setting, withdrawals, dates of study.
2. Participants: N, mean age, age range, sex, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, time points reported.
5. Notes: funding for trial, notable conflicts of interest of trial
authors.
Two review authors (KMK and KD) independently extracted out-
come data from included studies. We noted in the ’Characteristics
of included studies’ table if outcome data were not reported in
a useable way. We resolved disagreements by consensus. One re-
view author (KMK) transferred data into the Review Manager file
(RevMan 2014). We double-checked that data had been entered
correctly by comparing data presented in the systematic review
versus information provided in the study reports.
Assessment of risk of bias in included studies
Two review authors (KMK and KD) independently assessed risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
and we resolved disagreements by discussion. We assessed risk of
bias according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low, or unclear and
provided a quote from the study report together with a justification
for our judgement in the ’Risk of bias’ table. We summarised
risk of bias judgements across different studies for each of the
domains listed.We considered blinding separately for different key
outcomes when necessary (e.g. for unblinded outcome assessment,
risk of bias for all-cause mortality may be very different than for
a patient-reported pain scale). When information on risk of bias
related to unpublished data or correspondence with a trialist, we
noted this in the ’Risk of bias’ table.
When considering treatment effects, we took into account risk of
bias for studies that contributed to each outcome separately.
Assessment of bias in conducting the systematic
review
We conducted the review according to our published protocol and
reported deviations from it in the ’Differences between protocol
and review’ section of the systematic review (Kew 2015).
Measures of treatment effect
We analysed dichotomous data as odds ratios (OR), and contin-
uous data as mean differences (MD) or standardised mean differ-
ences (SMD). We entered data presented as a scale with a con-
sistent direction of effect. We narratively described skewed data
reported as medians and interquartile ranges. We analysed data
from cross-over trials using generic inverse variance (GIV), only if
double-counting of participants had been accounted for. If trials
presented both raw data and adjusted analyses (e.g. accounting for
baseline differences), we used the latter.
We undertook meta-analyses only when meaningful (i.e. if treat-
ments, participants and underlying clinical questions were similar
enough for pooling to make sense).
When a single trial reported multiple trial arms, we included only
the relevant arms. If two comparisons (e.g. drug A vs placebo and
drug B vs placebo) were combined in the same meta-analysis, we
halved the control group to avoid double-counting.
If both change from baseline and endpoint scores were available
for continuous data, we used change from baseline unless most
studies reported endpoint scores. If a study reported outcomes at
multiple time points, we used the end-of-study measurement.
When both an analysis including only participants who completed
the trial and an analysis that imputed data for participants who
were randomly assigned but did not provide endpoint data (e.g.
last observation carried forward) were available, we used the latter.
For dichotomous outcomes, we assumed equivalence of treatments
only if the OR estimate and its 95% confidence interval fell be-
tween the predefined arbitrary limits of 0.9 and 1.1.
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Unit of analysis issues
For dichotomous outcomes, we used participants rather than
events as the unit of analysis (i.e. number of adults admitted to
hospital rather than number of admissions per adult). However,
if exacerbations were reported as rate ratios, we analysed them on
this basis. For cross-over trials, we included data only if we could
analyse them appropriately using generic inverse variance to con-
trol for intercorrelation of matched pairs.
Dealing with missing data
We contacted investigators or study sponsors to verify key study
characteristics and obtained missing numerical outcome data
when possible (e.g. when a study was reported as abstract only).
When this was not possible and the missing data were thought
to introduce serious bias, we performed a sensitivity analysis to
explore the impact of including such studies in the overall assess-
ment of results.
Assessment of heterogeneity
We used the I2 statistic to measure heterogeneity among the trials
in each analysis. If we identified substantial heterogeneity, we re-
ported this and explored possible causes by prespecified subgroup
analysis.
Assessment of reporting biases
If we were able to pool more than 10 trials, we created and exam-
ined a funnel plot to explore possible small study and publication
biases.
Data synthesis
We used a random-effects model and performed a sensitivity anal-
ysis with a fixed-effect model if the I2 value was greater than 30%.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses for the
primary outcomes, using the formal test for subgroup differences
in Review Manager 5 (RevMan 2014).
1. Duration of therapy (≤ 6 months vs > 6 months).
2. Dose and type of LABA/ICS (e.g. formoterol/budesonide
9/320 vs salmeterol/fluticasone 50/250 µg).
3. Dose and type of LAMA (e.g. tiotropium HandiHaler 18
µg vs tiotropium Respimat 5 µg).
Sensitivity analysis
We planned to carry out sensitivity analyses for the primary out-
comes by excluding the following.
1. Studies at high risk of bias for blinding of participants and
personnel.
2. Unpublished data (i.e. no peer-reviewed full paper
available).
3. Cross-over trials.
’Summary of findings’ table
We created a ’Summary of findings’ table using the seven prespec-
ified outcomes from our protocol (Kew 2015). We used the five
Grades of Recommendation, Assessment, Development and Eval-
uation (GRADE) considerations (study limitations, consistency
of effect, imprecision, indirectness and publication bias) to assess
the quality of the body of evidence as it related to studies that con-
tributed data to the meta-analyses for prespecified outcomes. We
used methods and recommendations as described in Section 8.5
and Chapter 12 of the Cochrane Handbook for Systematic Reviews
of Interventions and used GRADEpro software (Higgins 2011).
We justified all decisions to downgrade or upgrade the quality of
studies by using footnotes, and we made comments when neces-
sary to aid readers’ understanding of the review.
R E S U L T S
Description of studies
Results of the search
We screened the titles and abstracts of 84 records identified in
the main electronic search conducted in January 2016. We also
looked for trials in a similar, less specific search in October 2014
(71 records) and from theWHO trials portal (45 records), the EU
clinical trials register (28 records), ClinicalTrials.gov (27 records),
and theNovartis trial registry (7 records).We attempted searches of
Boehringer Ingelheim and AstraZeneca, which also make LAMA
products, but these websites linked directly to the registries we had
already searched. We removed 83 duplicate records and screened
the titles and abstracts of the remaining 179 records. Both au-
thors agreed to exclude 105 records after viewing titles and ab-
stracts, and we reviewed full-text articles for the other 74 records.
At this stage, we excluded 36 with reasons, collating them into 28
excluded studies (see Excluded studies) plus one ongoing study.
Thirty-six records relating to four unique studies met the inclusion
criteria, with many of these listed under both Kerstjens 2012a and
Kerstjens 2012b, as the reports described both trials. We present
the study flow in Figure 1.
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Figure 1. Study flow diagram.
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Included studies
Four studies met the inclusion criteria, one of which was with-
drawn prior to enrolment (NCT02127697). The other three stud-
ies were all multicentre, parallel, double-blind, double-dummy
randomised controlled trials sponsored by Boehringer-Ingelheim.
Two were 48-week twin trials conducted at over 70 study centres
in multiple countries (the twin trials were registered separately as
Kerstjens 2012a and Kerstjens 2012b, but other reports of the
studies treated the trials as twins) and one was a 52-week study
conducted across 55 sites in Japan (Ohta 2014). Kerstjens 2012a
and Kerstjens 2012b randomised patients to one of two groups,
tiotropium Respimat at a dose of 5 µg once daily or placebo. Ohta
2014 was a three-arm study randomising people to receive one of
two doses of tiotropium Respimat, 2.5 µg or 5 µg daily, or placebo.
The total number of participants randomised to the three com-
pleted studies was 1197. Summary characteristics of the included
studies are shown in Table 1.
The three completed studies had similar designs and recruited
similar cohorts of patients. Inclusion criteria that were common
across the trials were that patients were aged between 18 and 75
years, diagnosed with asthma before age 40 as confirmed at screen-
ing with a range of similar lung function requirements, and had
a score of at least 1.5 on the ACQ to confirm that it was symp-
tomatic. All studies excluded patients with chronic obstructive
pulmonary disorder (COPD) and other unstable medical illnesses
as well as patients who were current smokers or had a pack-year
history of more than 10 years. Stipulations regarding concomitant
drug use were comparable, requiring that treatment with other
asthma drugs had stopped at least four weeks before enrolment.
The twin trials were more stringent with criteria relating to the
duration and severity of asthma, requiring participants to have
at least a five-year history of asthma, at least one exacerbation
needing treatment with systemic glucocorticoids in the previous
year, and stable high doses of LABA/ICS. Ohta 2014 required
only a 12-week history of symptomatic asthma, and crucially that
participants could be taking stable medium doses of ICS, “alone or
in a fixed combination with a LABA, for at least four weeks”. This
meant that a subset of participants in the latter study were only
taking ICS and did not meet the criteria for this review, but we
chose to include the study because baseline data showed that 56.8
percent were taking a LABA.We did not anticipate this possibility
and so assessed its impact with sensitivity analyses and downgraded
the quality in the GRADE assessment for indirectness of the study
population.
Excluded studies
Of the 38 articles we excluded after viewing full texts,
NCT01696214 was listed as an ongoing study, and 37 records re-
lated to 28 excluded studies that did not meet the inclusion crite-
ria. The most common reason for exclusion was that participants
were excluded if they were taking regular LABA/ICS; these studies
assessed tiotropium for people with less severe asthma who were
currently taking ICSmonotherapy.We excluded 7 articles because
they described studies shorter than 12 weeks, 5 because they were
reports of meta-analyses rather than RCT reports, 2 because they
compared the wrong treatments, 1 because the control group had
emphysema, and 1 because the study recruited adolescents under
18 years.
Risk of bias in included studies
We rated the three completed studies contributing data to the
meta-analyses as having low risk of bias across domains (see Figure
2). We judged the remaining study to be at unclear or high risk of
bias across the domains, mainly because it was withdrawn without
explanation before enrolling participants.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The three completed studies were all at low risk of selection bias.
They were all published in peer-reviewed journals and adequately
described methods of random sequence generation using comput-
erised random number generators, and allocation concealment us-
ing web- or phone-based automated allocation systems. We were
unable to make a judgement about the withdrawn study for selec-
tion bias as it did not enrol any participants.
Blinding
All three studies contributing to the meta-analyses were double-
blind until after database lock by means of matching placebo in-
halers. As such, all trials were at low risk of performance and de-
tection bias. As with selection bias, we were unable to make a
judgement about the study that was withdrawn.
Incomplete outcome data
The three completed studies all had dropout below 15% across the
included arms. They all used the intention-to-treat population for
the analyses, which included all patients who received at least one
dose of the study medication the vast majority of randomised
participants in all three studies. Aswith the other domains, wewere
unable to make a judgement about the study that was withdrawn.
Selective reporting
All of the studies had registered protocols so it was possible to
compare the prospective list of outcomes with the reported data.
The three completed studies reported all outcomes in full and so
we rated them as having low risk of bias. We rated the withdrawn
study as at high risk of bias because, although no participants were
enrolled, there was no publicly available information about the
reasonswhy the study did not go ahead, and the information about
the study was not sufficient to assess bias thoroughly.
Other potential sources of bias
We did not observe any other sources of bias in three studies, but
we note the fact that NCT02127697 was withdrawn as a high risk
of bias, as it was not clear why this occurred.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings table 1
We present evidence for the primary and secondary outcomes with
an assessment of the quality of evidence in Summary of findings for
the main comparison. While the review aimed to assess evidence
for any LAMApreparation, the results are currently for tiotropium
Respimat only.
Primary outcomes
Exacerbations requiring oral corticosteroids
Fewer people taking tiotropium add-on had exacerbations that
needed treatment with oral corticosteroids, but the confidence
intervals (CIs) for the effect estimate included no difference (OR
0.76, 95% CI 0.57 to 1.02; participants = 907; studies = 2; I2 =
1%; Analysis 1.1). Over 48 weeks, 328 out of 1000 people taking
their usual LABA/ICS would have to take oral corticosteroids for
an exacerbation compared with 271 if they also took tiotropium,
but the confidence intervals ranged from 218 to 333 per 1000.
This imprecision is partly explained by there only being two studies
in the analysis, which observed fewer than 300 events between
them, and we downgraded the evidence to moderate quality for
this reason.
We also looked at data for the number of exacerbations per patient,
which accounted for people who had multiple exacerbations dur-
ing the study period. The rate ratio for this outcome was in favour
of adding tiotropium but the confidence intervals included a pos-
sible benefit of LABA/ICS alone (rate ratio 0.79, 95% CI 0.53 to
1.17; participants = 907; studies = 2). An analysis of time to the
first exacerbation also favoured tiotropium add-on, but again the
confidence intervals did not rule out no effect (hazard ratio 0.80,
95% CI 0.63 to 1.01; participants = 907; studies = 2).
Quality of life
Two studies reporting scores from the Asthma Quality of Life
Questionnaire (AQLQ) did not show a benefit of tiotropium over
LABA/ICS alone (MD 0.09, 95% CI− 0.03 to 0.20; participants
= 907; studies = 2; I2 = 0%; Analysis 1.4). The effect estimate
favoured tiotropium add-on, but the confidence intervals included
a benefit of LABA/ICS alone, and they were both well within the
minimal clinically important difference for the scale (0.5).
Serious adverse events (all causes)
The effect estimate suggested fewer serious adverse events when
people took tiotropium, but the difference against LABA/ICS
alone was not statistically significant, and there was a large degree
of inconsistency between individual studies (OR 0.60, 95% CI
0.24 to 1.47; participants = 1197; studies = 3; I2 = 76%; Analysis
1.5). Pooling all three studies, the confidence intervals included
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appreciable harm on either treatment, largely because Ohta 2014
had a much larger effect in favour of tiotropium. Ohta 2014 was
different from the other two studies because it combined two dose
groups in the analysis. In addition, the study included partici-
pants who were taking either ICS alone as background treatment
or LABA/ICS. Consequently, some results are from participants
who do not meet all inclusion criteria for this review. A post hoc
sensitivity analysis removing this studymade the effectmuchmore
precise but did not change the interpretation that there was not a
clear difference. We downgraded for inconsistency and indirect-
ness but not for imprecision, and so rated it as low quality.
Secondary outcomes
Exacerbations requiring hospital admission
Tiotropium add-on did not reduce the number of people needing
to go to hospital for an exacerbation of their asthma (OR 0.68,
95% CI 0.34 to 1.38; participants = 1191; studies = 3; I2 = 11%;
Analysis 1.6).While therewere slightlymore hospital visits in those
not taking tiotropium, the difference between groups was not sta-
tistically significant, and the confidence intervals were wide. Ohta
2014 showed a much larger effect in favour of tiotropium add-on
than the other two studies, which may be due to the indirectness
of the population, as described above. However, the effect in this
study carried less weight because it was based on very few events,
and the confidence intervals included the effects of the other two
studies. Removing the study in a post hoc sensitivity analysis on
the basis of an indirect population did not significantly improve
the precision of the estimate. We downgraded the evidence for
indirectness and imprecision, rating it as low quality.
Lung function
Change in lung function, asmeasured by trough FEV1, was 0.07 L
better in those taking tiotropium in addition to LABA/ICS (MD
0.07, 95% CI 0.03 to 0.11; participants = 1191; studies = 3; I2
= 0%; Analysis 1.7). The study with a partly indirect population
contributed to this outcome, but its results were not inconsistent
with the other studies, so we did not downgrade the evidence for
indirectness, rating it as high quality. We also analysed a second
lung function measure that was reported in three studies, and the
results were consistent with a modest benefit of tiotropium add-
on over LABA/ICS alone (trough FVC: MD 0.07, 95% CI 0.02
to 0.13; participants = 1191; studies = 3; I2 = 0%; Analysis 1.8).
Asthma control
Scores on the Asthma Control Questionnaire (ACQ) were slightly
better with tiotropium add-on compared with LABA/ICS alone,
but the difference was not clinically significant (MD− 0.13, 95%
CI − 0.23 to − 0.02; participants = 907; studies = 2; I2 = 0%;
Analysis 1.9). We did not downgrade the evidence and rated it as
high quality.
We also found data for the number of people meeting the criteria
for ’response’ on the ACQ (an improvement in the total score of
at least 0.5 points). The twin trials and one other study reported
this outcome as a pooled result; it favoured of tiotropium add-on,
but the confidence intervals did not exclude the possibility that
people on LABA/ICS alone did better (OR 1.42, 95% CI 0.88 to
2.29; participants = 1192; studies = 2; I2 = 51%; Analysis 1.10).
Any adverse events
People taking tiotropium add-on were less likely to have adverse
events than those taking LABA/ICS alone (OR 0.70, 95%CI 0.52
to 0.94; participants = 1197; studies = 3; I2 = 0%; Analysis 1.11).
The study with an indirect population contributed to this out-
come, but its results were not inconsistent with the other studies,
so we did not downgrade the evidence for indirectness, rating it
as high quality.
Subgroup analysis and investigation of heterogeneity
Duration of therapy (≤ 6 months vs > 6 months)
All of the studies lasted longer than six months, so it was not
possible to explore a possible effect of study duration through a
subgroup analysis. However, at times studies reported some out-
comes at midpoint (either 24 or 26 weeks) and endpoint (48 or
52 weeks). Within the primary outcomes, this was only true for
the AQLQ, and results were not different at the midpoint than
at the primary endpoint analysis (MD 0.11, 95% CI − 0.03 to
0.24 at 24 weeks; MD 0.09, 95% CI − 0.03 to 0.20 at 48-week
endpoint; Analysis 1.12).
Dose and type of LABA/ICS (e.g. formoterol/budesonide
9/320 vs salmeterol/fluticasone 50/250 µg)
The included studies required participants to be taking LABA/ICS
but did not include a particular combination product as part of the
randomised treatment (i.e. participants continued with whatever
they were taking prior to the trial). The twin trials required par-
ticipants to be taking stable high doses of LABA/ICS, and Ohta
2014 required participants to be taking stable medium doses of
ICS, “alone or in a fixed combination with a LABA, for at least
four weeks”. As such, we could not make a clear comparison across
studies on the basis of different types or doses of background treat-
ment.
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Dose and type of LAMA (e.g. tiotropium HandiHaler 18 µg
vs tiotropium Respimat 5 µg)
The twin trials both compared tiotropium Respimat 5 µg with
placebo, and only these two studies appeared in the analyses for
exacerbations requiring oral steroids and quality of life. In the third
primary outcome, serious adverse events, the effect in the third
study, which included an additional group receiving 2.5 µg Ohta
2014, was much more in favour of LAMA add-on, but this could
not be explained by dose (4/114 events in each groups). Within-
study analyses in Ohta 2014 showed that “adjusted mean trough
FEV1 and trough PEFR [peak expiratory flow rate] responses were
significantly higher with tiotropium 5 µg (but not 2.5 µg) versus
placebo” at week 52, but differences between the two doses were
not statistically significant for other outcomes.
Sensitivity analyses
Studies at high risk of bias for blinding of participants and
personnel
All of the studies were at low risk of bias for these domains, so it
was not necessary to conduct this planned sensitivity analysis.
Unpublished data (i.e. no peer-reviewed full paper available)
Athough there was not always a peer-reviewed publication avail-
able, all of the studies were registered, and all of the data included
in the meta-analysis were freely available on ClinicalTrials.gov. As
such, it was not necessary to conduct this sensitivity analysis.
Cross-over trials
No cross-over trials met the inclusion criteria, so it was not neces-
sary to conduct this planned sensitivity analysis.
D I S C U S S I O N
Summary of main results
We found four double-blind, double-dummy trials that compared
LAMA to placebo for people with asthma who were already taking
combination LABA/ICS. One of the trials was designed to study
glycopyrronium bromide but was withdrawn prior to enrolment,
and the three others studied tiotropium bromide over 48 to 52
weeks. People in the trials generally had quite poor lung function,
with FEV1 of around 55% of their predicted value.
People randomised to take a LAMA add-on had fewer exacerba-
tions requiring oral corticosteroids than those continuing to take
LABA/ICS alone, although the confidence intervals included no
difference (OR 0.76, 95% CI 0.57 to 1.02), so we considered the
evidence to be moderate quality. Over 48 weeks, 328 out of 1000
people taking their usual LABA/ICS would have to take oral cor-
ticosteroids for an exacerbation compared with 271 if they took a
LAMA aswell (95%CI 218 to 333 per 1000). Analyses comparing
the number of exacerbations per patient in each group (rate ratio)
and the time until first exacerbation (hazard ratio) were in keeping
with the main result. Quality of life (AQLQ) was no better for
those taking LAMA add-on than those taking LABA/ICS alone
when considered in light of the 0.5 minimal clinically important
difference on the scale (MD 0.09, 95% CI − 0.03 to 0.20), and
evidence for whether LAMA increased or decreased serious ad-
verse events in this population was inconsistent (OR 0.60, 95%
CI 0.24 to 1.47; I2 = 76%).
Within the secondary outcomes, exacerbations requiring hospi-
tal admission were too rare to tell whether LAMA was beneficial
over LABA/ICS alone, and we considered the evidence to be low
quality. There was high quality evidence showing benefits to lung
function (trough FEV1 and FVC) and potentially small benefits
to asthma control. People taking a LAMA add-on were less likely
to experience non-serious adverse events.
Overall completeness and applicability of
evidence
We found a limited number of studies that met the inclusion cri-
teria for our review, and there were differences between them that
need to be considered when interpreting the evidence. Ohta 2014
enrolled a patient population with less severe asthma, allowing
people to participate if they were only on background treatment
with stable medium-dose ICS and if their asthma symptoms had
occurred for as little as 12 weeks. This is in contrast to the twin
studies, where the patients had to have persistent airway limitation
despite a background therapy of high dose inhaled glucocorticoids
with LABAs and at least one exacerbation that was treated with
systemic glucocorticoids in the previous year (Kerstjens 2012a;
Kerstjens 2012b). The difference in asthma severity translates
to different points of pharmacotherapy management within the
asthma treatment algorithm. When determining the appropriate
step to initiate LAMA therapy, it is imperative to know at what
stage of asthma drug management provides the most benefit to
patients. In addition, all of the trials evaluated the addition of a
LAMA versus placebo. There were no trials that were included in
the review that directly compared the addition of a LAMA to the
addition of another active comparator.
Previous reviews that have evaluated LAMA addition to inhaled
corticosteroids have indicated that trials need durations of at least
six months in order to identify exacerbations (Anderson 2015).
While the trials included in this review were of sufficient duration,
from 48 to 52 weeks, exacerbations requiring hospital admission
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occurred at too low of a rate to assess whether there was a benefit
of LAMA add-on.
The included trials investigated the addition of tiotropium deliv-
ered via the Respimat device. The one trial that was withdrawn
prior to completion was going to investigate the use of glycopyrro-
nium (NCT02127697). Tiotropium delivered via the Handihaler
device and the newer LAMA agents such as umeclidinium and
aclidinium that have recently been released have yet to be evalu-
ated in the treatment of asthma. We cannot be certain that the re-
sults that we have seen with tiotropium delivered via the Respimat
device will be consistently found within this therapeutic class. The
studies added tiotropium Respimat to LABA/ICS therapy; how-
ever the exact LABA/ICS combination was not specified. The twin
trials required participants to be taking stable high doses of LABA/
ICS (Kerstjens 2012a; Kerstjens 2012b), and Ohta 2014 required
participants to be taking stable medium doses of ICS alone or in
a fixed combination with a LABA. As with all study-based sub-
group analyses, comparing the high dose LABA/ICS trials to the
medium dose trial would be an observational result that could be
confounded by any number of other factors (age, tiotropium dose,
adherence, comorbidities, the presence and type of LABA). As
such, especially given the small number of trials that are currently
available, we did not feel able to draw conclusions regarding the
benefits or harms of tiotropium according to the background dose
of LABA/ICS.
The evidence that we found did not suggest that LAMAs increased
the risk of serious adverse events. However, the trials included
a limited number of patients with strict inclusion criteria. Drug
companies sponsored all of the included studies. While generally
we found them to have low risk of bias, the use of LAMAs outside
a strict study environment may lead to either different effects on
the measured outcomes or signals for adverse events.
Quality of the evidence
Our confidence in the evidence varied considerably across the
primary and secondary outcomes. The most common reason for
downgrading evidence quality was imprecision in the estimates,
which was partly due to the relatively small number of studies. In
addition, for rarer events such as exacerbations requiring hospital
admission and serious adverse events, longer studies would be
better able to assess any difference between groups more robustly.
Only the analyses on quality of life, lung function, asthma control
and any adverse events included sufficient people or events to
confer confidence in the direction of effect; due to the width of the
confidence intervals, we could not conclude that LAMA add-on
was better than LABA/ICS alone for exacerbations requiring oral
corticosteroids, serious adverse events or exacerbations requiring
hospital admission.
Ohta 2014 introduced indirectness into some of the analyses,
which we tested and described with post hoc sensitivity analyses.
The study required participants to be taking ICS with or without
a LABA, so some participants did not meet the prespecified inclu-
sion criteria for this review and may have had less severe asthma.
The results of this study introduced clinical and statistical hetero-
geneity into the serious adverse events analysis in particular, but
also into the analysis of exacerbations requiring hospital admis-
sion and ACQ responders. It was the only study to include two
doses of tiotropium Respimat, which may also have contributed
to differences with the other studies.
Despite these limitations, we did not consider any of the analyses
to be compromised by internal risk of bias in the included studies,
which were all double-blind, double-dummy randomised trials.
Nor did we suspect publication bias either within the included
studies or due to the absence of other unpublished trials. How-
ever, we note that the glycopyrronium trial NCT02127697 was
withdrawn without explanation, and that all of the studies were
funded by industry, and this represents a potential for bias in the
evidence base.
Potential biases in the review process
We closely followed the methods set out in our review protocol
(Kew 2015), which was developed in line with Cochrane guide-
lines. In addition to trial registry searches required byCochrane,we
conducted extensive additional searches ofmanufacturer databases
to identify unpublished studies. Industry-funded studies con-
ducted since the development of LAMAs should all have been
registered and reported on trial registries, but it is possible that
other independent studies have been conducted and not yet made
available.
It is possible that the decision to include Ohta 2014 in this review
introduced bias, although we considered this eventuality through-
out the review process and fully addressed it with sensitivity anal-
yses and the respective GRADE ratings for analyses to which the
trial contributed.
Agreements and disagreements with other
studies or reviews
There have been three other meta-analyses that have investi-
gated the addition of LAMA for patients with asthma (Lee 2014;
Rodrigo 2015; Tian 2014). All three included only trials that eval-
uated tiotropium. The most recent publication included patients
aged 12 years and over who were receiving maintenance therapy
with either an inhaled corticosteroid or an inhaled corticosteroid
plus a LABA for a minimum duration of four weeks (Rodrigo
2015). Reviewers divided the thirteen studies that met the inclu-
sion criteria into three treatment groups: tiotropium once daily
as an add-on to ICS in patients with mild to moderate asthma,
tiotropium once daily added to ICS versus twice daily LABA/ICS
in patients with moderate asthma, and tiotropium once daily as
add-on to LABA/ICS versus LABA/ICS in patients with severe
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asthma. The last treatment group had three studies and was com-
parable to the focus of our meta-analysis. However, only one of the
included studies also met our inclusion criteria; we had to exclude
the other two because they were too short in duration for our re-
view. The review found an improvement in FEV1 with addition
of the LAMA. Reviewers defined exacerbations as the number of
patients with one or more episodes requiring the use of systemic
corticosteroids, and they concluded that the number needed to
treat for an additional beneficial outcome (NNTB) was 17 for this
outcome, with a difference in occurrence of 18.2% versus 24.0%.
This differs from our findings, which did not show a statistically
significant difference.
Rodrigo 2015 was the only one of the three publications that
separately evaluated the addition of LAMA to LABA/ICS. The
remaining two publications included trials with different back-
ground therapies, which they analysed together (Lee 2014; Tian
2014). Lee 2014 included a total of five studies, which varied from
adding tiotropium to various ICS doses to adding tiotropium to
LABA/ICS combination therapy. They found similar improve-
ments in FEV1 in addition to a decrease in the odds of having a
severe acute exacerbation of asthma (OR 0.73, 95% CI 0.56 to
0.96). However, their definition of this outcome was an exacer-
bation that showed a decline in a patient’s respiratory symptoms
leading to the use of systemic corticosteroids or the increased use
of ICS or other asthma medications, and only two of the trials
actually evaluated this outcome. Tian 2014 also included a mix of
studies that evaluated either ICS alone or combinations of LABA/
ICS as background therapy. In addition, one of the included trials
evaluated tiotropium in adolescents aged 12 to 17 years old. De-
spite these differences, their statistical analysis yielded similar re-
sults to what we found: asthma exacerbations were less frequent in
the tiotropium group (OR 0.70, 95% CI 0.52 to 0.96, P = 0.02).
However, they did not provide a definition for this outcome.
None of the above trials found an increase in adverse events with
the addition of tiotropium (Lee 2014; Rodrigo 2015; Tian 2014),
and this review suggests that tiotropium may lead to fewer non-
serious adverse events than using LABA/ICS alone.
There have been a number of trials and meta-analyses that have
evaluated the use of tiotropium as an add-on to ICS alone. These
trials have found improvements in peak expiratory flow (PEF),
FEV1 and more importantly, the occurrence of asthma exacerba-
tions, with the addition of tiotropium (Anderson 2015; Rodrigo
2015).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Tiotropium add-on may have additional benefits over LABA/ICS
alone to reduce the need for rescue oral steroids in people with
severe asthma.The effect was imprecise, and there was no evi-
dence for other LAMA preparations. Possible benefits on quality
of life were negligible, and evidence for the effect on serious ad-
verse events was inconsistent. There are likely to be small added
benefits of tiotropium Respimat 5 µg daily on lung function and
asthma control over LABA/ICS alone, and fewer non-serious ad-
verse events. The benefit of tiotropium add-on on the frequency
of hospital admission is not yet known, despite year-long trials.
Implications for research
Ongoing and future trials should be clear about the background
medications taken by participants to help clinicians judge how the
findings relate to stepwise care. If LAMAs other than tiotropium
Respimat are tested for asthma, trials should be at least six months
long and use accepted and validated outcomes to allow compar-
isons between the safety and effectiveness of different preparations.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Kerstjens 2012a
Methods Study design: 48-week, parallel, double-blind RCT
Setting: 73 study centres in 14 countries (Australia, Canada, Denmark, Germany, Italy,
Japan, Netherlands, Russia, Serbia, South Africa, Turkey, Ukraine, United Kingdom,
United States)
Participants Population: 459 people were randomised to receive tiotropium or placebo
Baseline characteristics:
N randomised: tiotropium 237; placebo 222
N completed: tiotropium 211; placebo 202
Mean age (SD): tiotropium 52.9 (12.4); placebo 53.9 (12.8)
% male: tiotropium 38.4; placebo 35.6
% predicted FEV1(SD): tiotropium 54.6 (12.2); placebo 54.6 (12.2)
Duration of asthma, years (SD): tiotropium 31 (NR); placebo 28 (NR)
Inclusion criteria: informed consent form; male or female patients aged 18-75 years;≥
5-year history of asthma and diagnosis made before age 40; diagnosis of severe persistent
asthma that is symptomatic despite treatment with high, stable doses of ICS and a
LABA; history of≥ 1 asthma exacerbation(s) in the past year; evidence of treated, severe,
persistent asthma in post bronchodilatory pulmonary function tests; never-smokers or
ex-smokers who stopped smoking ≥ 1 year prior to enrolment and who have a smoking
history of < 10 pack-years; able to use the Respimat inhaler correctly; able to perform all
trial-related procedures including technically acceptable pulmonary function tests and
use of the electronic diary/peak flow meter
Exclusion criteria: significant disease other than asthma; clinically relevant abnormal
screening haematology or blood chemistry; recent history (i.e. ≤ 6 months) of myocar-
dial infarction, hospitalisation for cardiac failure during the past year, cardiac arrhythmia
requiring treatment within the past year, known active TB, resection, radiation or che-
motherapy for malignancy within previous 5 years (treated basal cell carcinoma allowed)
, lung diseases other than asthma (e.g. COPD), significant alcohol or drug abuse within
previous 2 years, thoracotomy with pulmonary resection; current or recent pulmonary
rehabilitation program (previous 6 weeks); OCS at stable doses > 5 mg prednisolone
equivalent daily or 10 mg every second day; known hypersensitivity to anticholinergic
drugs or any components of the tiotropium inhaler; pregnant or nursing women or
women of childbearing potential not using a highly effective method of birth control;
investigational drug use within 4 weeks or 6 half-lives (whichever is greater); treated in
the previous 4 weeks with tiotropium (Spiriva), beta-blocker, oral beta-adrenergic, or
other non-approved ’experimental’ drugs for routine asthma therapy that are not recom-
mended by international guidelines; any asthma exacerbation or RTI in the 4 weeks prior
to the trial; previously randomised in this trial or in the respective twin trial (Kerstjens
2012b) or currently participating in another trial; known narrow-angle glaucoma
Interventions Intervention: tiotropium Respimat 5 µg once daily
Control: placebo Respimat inhaler taken once daily
Background treatment: usual treatment with high, stable doses of inhaled corticos-
teroids and a long-acting beta adrenergic agent
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Kerstjens 2012a (Continued)
Outcomes Primary: peak FEV1 response within 3 h post dosing after 24 weeks, trough FEV1
response after 24 weeks, time to first severe exacerbation during 48 weeks (pooled with
twin trial)
Secondary: range of lung function measures at 24 and 48 weeks (peak FEV1 0-3 hours,
trough FEV1, peak FVC, trough FVC, FEV1 AUC, FVC AUC, trough morning and
evening PEF, PEF variability), all exacerbations and severe exacerbations (time to first,
number per patient, and number of patients with at least 1), hospitalisations for exac-
erbations (time to first, number per patient, and number of patients with at least 1),
AQLQ total score, ACQ, symptom-free days, rescue medication use
Notes Funding: Boehringer Ingelheim with collaboration from Pfizer
ID number(s): NCT00772538; PrimoTinA-asthma 1; 205.416; 2008-001413-14
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization schedule was gener-
ated by a validated system (PMXCTM, re-
lease 3.3.0 HP2, Propack Data) with the
use of a pseudo-random number generator
and a supplied seed number.”
Allocation concealment (selection bias) Low risk “The randomisation code will be kept
by Clinical Trial Support (within Medical
Data Services/Biostatistics and Data Man-
agement) up to database lock. They will
only release it according to this protocol.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Patients, investigators, and everyone in-
volved in the analysis or with an inter-
est in this double-blind trial (except mem-
bers of the independent data monitoring
committee for the unblinded interim anal-
ysis) will remain blinded with regard to the
randomised treatment assignments up to
database lock unless foreseen otherwise in
this protocol.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Patients, investigators, and everyone in-
volved in the analysis or with an inter-
est in this double-blind trial (except mem-
bers of the independent data monitoring
committee for the unblinded interim anal-
ysis) will remain blinded with regard to the
randomised treatment assignments up to
database lock unless foreseen otherwise in
this protocol.”
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Kerstjens 2012a (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Patient dropout was 11% and 9% in the
treatment and control groups, respectively,
and the ITT population used for the analy-
ses included everyone who was randomised
and received at least 1 dose of medication
(appears to be everyone)
Selective reporting (reporting bias) Low risk Full trial results according to the published
protocol are available on ClinicalTrials.gov
and in a published paper with the twin trial
Other bias Low risk None noted
Kerstjens 2012b
Methods Study design: 48-week, parallel, double-blind RCT
Setting: 75 study centres in 15 countries (Australia, Canada, Denmark, Germany, Italy,
Japan, Netherlands,NewZealand, Russia, Serbia, South Africa, Turkey, Ukraine, United
Kingdom, United States)
Participants Population: 453 people were randomised to receive tiotropium or placebo
Baseline characteristics:
N randomised: tiotropium 219; placebo 234
N completed: tiotropium 198; placebo 203
Mean age (SD): tiotropium 51.4 (12.5); placebo 53.6 (11.7)
% male: tiotropium 42.0; placebo 42.3
% predicted FEV1(SD): tiotropium 55.1 (12.8); placebo 55.0 (12.6)
Duration of asthma, years (SD): tiotropium 26 (NR); placebo 28 (NR)
Inclusion criteria: informed consent form; male or female patients aged 18-75 years;≥
5-year history of asthma and diagnosis made before age 40; diagnosis of severe persistent
asthma that is symptomatic despite treatment with high, stable doses of ICS and a
LABA; history of≥ 1 asthma exacerbation(s) in the past year; evidence of treated, severe,
persistent asthma in postbronchodilatory pulmonary function tests; never-smokers or
ex-smokers who stopped smoking ≥ 1 year prior to enrolment and who have a smoking
history of < 10 pack-years; able to use the Respimat inhaler correctly; able to perform all
trial-related procedures including technically acceptable pulmonary function tests and
use of the electronic diary/peak flow meter
Exclusion criteria: significant disease other than asthma; clinically relevant abnormal
screening haematology or blood chemistry; recent history (i.e. ≤ 6 months) of myocar-
dial infarction, hospitalisation for cardiac failure during the past year, cardiac arrhythmia
requiring treatment within the past year, known active TB, resection, radiation or che-
motherapy for malignancy within previous 5 years (treated basal cell carcinoma allowed)
, lung diseases other than asthma (e.g. COPD), significant alcohol or drug abuse within
previous 2 years, thoracotomy with pulmonary resection; current or recent pulmonary
rehabilitation program (previous 6 weeks); OCS at stable doses > 5 mg prednisolone
equivalent daily or 10 mg every second day; known hypersensitivity to anticholinergic
drugs or any components of the tiotropium inhaler; pregnant or nursing women or
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Kerstjens 2012b (Continued)
women of childbearing potential not using a highly effective method of birth control;
investigational drug use within 4 weeks or 6 half-lives (whichever is greater); treated in
the previous 4 weeks with tiotropium (Spiriva), beta-blocker, oral beta-adrenergic, or
other non-approved ’experimental’ drugs for routine asthma therapy that are not recom-
mended by international guidelines; any asthma exacerbation or RTI in the 4 weeks prior
to the trial; previously randomised in this trial or in the respective twin trial (Kerstjens
2012a) or currently participating in another trial; known narrow-angle glaucoma
Interventions Intervention: Tiotropium Respimat 5 µg once daily
Control: Placebo Respimat inhaler taken once daily
Background treatment: usual treatment with high, stable doses of inhaled corticos-
teroids and a long-acting beta adrenergic agent
Outcomes Primary: peak FEV1 response within 3 hours postdosing after 24 weeks, trough FEV1
response after 24 weeks, time to first severe exacerbation during 48 weeks (pooled with
twin trial)
Secondary: range of lung function measures at 24 and 48 weeks (peak FEV1 0-3 hours,
trough FEV1, peak FVC, trough FVC, FEV1 AUC, FVC AUC, trough morning and
evening PEF, PEF variability), all exacerbations and severe exacerbations (time to first,
number per patient, and number of patients with at least 1), hospitalisations for exac-
erbations (time to first, number per patient, and number of patients with at least 1),
AQLQ total score, ACQ, symptom-free days, rescue medication use
Notes Funding: Boehringer Ingelheim with collaboration from Pfizer
ID number(s): NCT00776984; PrimoTinA-asthma 2; 205.417; 2008-001414-25
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization schedule was gener-
ated by a validated system (PMXCTM, re-
lease 3.3.0 HP2, Propack Data) with the
use of a pseudo-random number generator
and a supplied seed number.”
Allocation concealment (selection bias) Low risk “The randomisation code will be kept
by Clinical Trial Support (within Medical
Data Services/Biostatistics and Data Man-
agement) up to database lock. They will
only release it according to this protocol.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Patients, investigators, and everyone in-
volved in the analysis or with an inter-
est in this double-blind trial (except mem-
bers of the independent data monitoring
committee for the unblinded interim anal-
ysis) will remain blinded with regard to the
randomised treatment assignments up to
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Kerstjens 2012b (Continued)
database lock unless foreseen otherwise in
this protocol”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Patients, investigators, and everyone in-
volved in the analysis or with an inter-
est in this double-blind trial (except mem-
bers of the independent data monitoring
committee for the unblinded interim anal-
ysis) will remain blinded with regard to the
randomised treatment assignments up to
database lock unless foreseen otherwise in
this protocol”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Patient dropout was 10% and 13% in the
treatment and control groups respectively,
and the ITT population used for the analy-
ses included everyone who was randomised
and received at least 1 dose of medication
(448/453 randomised)
Selective reporting (reporting bias) Low risk Full trial results according to the published
protocol are available on clinicaltrials.gov
and in a published format with the twin
trial
Other bias Low risk None noted
NCT02127697
Methods Study design: 52-week parallel, double-blind RCT
Setting: 30 countries listed, does not mention the number of participating centres
Participants Population: This trial was withdrawn before any participants were enrolled
Inclusion criteria: written informed consent; male and female adult patients aged 18-
75 years; diagnosis of asthma (according to GINA 2012) ≥ 5 years previous to trial,
made before the patient was 40; increase in FEV1 of ≥ 12% and ≥ 200 mL within 30
min of 400 µg salbutamol/360 µg albuterol (or equivalent); pre-bronchodilator FEV1
of ≥ 50 and ≤ 80% predicted normal; treated with a stable dose of a fixed dose inhaled
corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination for at least
4 weeks prior to screening; total daily dose of ICS of ≥ 800 µg/d of budesonide or
equivalent; symptomatic with a mean ACQ-5 score ≥ 1.5; documented history of ≥ 1
asthma exacerbations in the previous 12 months that required systemic corticosteroids,
emergency room visit, hospital treatment or intubation
Exclusion criteria: contraindicated for or hypersensitivity to any of the following in-
haled drugs, drugs of a similar class, or any component thereof: muscarinic antagonist
agents, sympathomimetic amines, lactose or any of the other excipients of the study drug,
long- and short-acting beta2-agonists, corticosteroids; women of child-bearing potential;
resting QTcF ≥ 450 ms (male) or ≥ 460 ms (female); BMI > 40 kg/m2; clinically sig-
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nificant comorbidity; asthma exacerbation that required systemic corticosteroids, emer-
gency room visit, hospital treatment or intubation in the 6 weeks prior to screening;
smoked or inhaled tobacco products within 6 months, or a smoking history of > 10 pack
years; history of chronic lung diseases other than asthma. Maintenance immunotherapy
for allergies must have been so for ≥ 3 months prior to run-in, and must be expected to
remain unchanged throughout the course of the study
Interventions Intervention: glycopyrronium bromide once daily - dose not specified
Control: placebo
Background treatment: stable dose of a fixed dose inhaled corticosteroid (ICS) and
long-acting beta2-agonist (LABA) combination for at least 4 weeks prior to screening
Outcomes Primary: trough FEV1 at 26 weeks
Secondary: time to first moderate or severe asthma exacerbation (52 weeks), ACQ (26
weeks), ACQ-5, ACQ-6 and ACQ-7 at various time points, AQLQ (12, 26, 52 weeks),
SGRQ (12, 26, 52 weeks), variety of lung function measures at day 1 and weeks 4, 26,
and 52 (peak FEV, FEV1 standardised AUC, predose FEV1, trough FEV1, morning and
evening PEF, FVC),mean daily number of puffs of rescuemedication, rate ofmoderate or
severe exacerbation, rate of severe exacerbation, time to first severe exacerbation, time to
first mild, moderate or severe exacerbation, rate of mild moderate or severe exacerbation,
asthma control diary symptom score
Notes WITHDRAWN PRIOR TO ENROLLMENT
Funding: Novartis Pharmaceuticals
ID number(s): NCT02127697, CNVA237B2301
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was withdrawn prior to enrolment
Allocation concealment (selection bias) Unclear risk No participants enrolled
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No participants enrolled
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No participants enrolled
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No participants enrolled
Selective reporting (reporting bias) High risk Study was withdrawn prior to enrolment
and hence no results are available and min-
imal methods reported on the trial registra-
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tion page
Other bias High risk Not clear why the study was withdrawn
Ohta 2014
Methods Study design: 52-week parallel, double-blind RCT
Setting: 55 Boehringer Ingelheim investigational sites in Japan
Participants Population: 285 people were randomised to receive tiotropium 2.5 µg, tiotropium 5
µg, or placebo (57)
Baseline characteristics:
N randomised: tiotropium low 114; tiotropium high 114; placebo 57
N completed: tiotropium low 106; tiotropium high 106; placebo 52
Mean age (SD): tiotropium low 44.7 (12.1); tiotropium high 42.6 (12.8); placebo 47.8
(13.0)
% male: tiotropium low 36.8; tiotropium high 42.1; placebo 33.3
% predicted FEV1(SD): NR
Duration of asthma, years (SD): NR
Inclusion criteria: informed consent; male or female outpatients aged 18-75 years; ≥
12-week history of asthma at enrolment, diagnosed before 40 years, and confirmed with
bronchodilator reversibility (15-30 min after 400 µg salbutamol) resulting in a FEV1
increase of at least 12% and at least 200 mL; on maintenance treatment with a medium,
stable dose of ICS (alone or in a fixed combination with a LABA) for at least 4 weeks prior
to visit 1; ACQ ≥ 1.5 at screening; pre-bronchodilator FEV1 60%-90% of predicted
normal at visit 1; never-smokers or ex-smokers for ≥ 1 year and a smoking history of <
10 pack-years; able to use the Respimat inhaler correctly; able to perform all trial-related
procedures
Exclusion criteria: lung or additional significant disease other than asthma; recent his-
tory (≤ 6 months) of myocardial infarction; hospitalised for cardiac failure within 1
year; any unstable or life-threatening cardiac arrhythmia or cardiac arrhythmia requiring
intervention or a change in drug therapy within 1 year; known active TB; malignancy
or treated for malignancy with resection, radiation therapy or chemotherapy within 5
years (treated basal cell carcinoma allowed); undergone thoracotomy with pulmonary
resection; significant alcohol or drug abuse within 2 years; known hypersensitivity to
anticholinergic drugs, benzalkonium chloride (BAC), ethylenediaminetetraacetic acid
(EDTA), or any other components of the study medication delivery systems; pregnant
or nursing women; women of childbearing potential not using a highly effective method
of birth control; taken an investigational drug, beta-blocker, tiotropium (Spiriva), oral
beta-adrenergic, systemic corticosteroids, or other non-approved/not guideline recom-
mended ’experimental’ drugs for asthma within 4 weeks prior to visit 1; topical cardios-
elective beta-blocker eye medications for non-narrow angle glaucoma are allowed; anti-
IgE antibodies, e.g. omalizumab (Xolair), within 6 months prior to visit 1 or during the
screening period; any asthma exacerbation or any respiratory tract infection in the four
weeks prior to visit 1 or during the screening period; currently participating in another
trial; narrow-angle glaucoma or micturition disorder due to prostatic hyperplasia; below
80% eDiary completion compliance on visit 2
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Interventions Intervention 1: Ttiotropium Respimat 2.5 µg once daily (low group)
Intervention 2: tiotropium Respimat 5 µg once daily (high group)
Control: placebo Respimat inhaler taken once daily
Background treatment: maintenance treatment with a medium, stable dose of inhaled
corticosteroids with or without a long-acting beta2-agonist. Continuation with pre-study
maintenance therapy and rescue salbutamol was permitted
Outcomes Primary: number of patients with drug-related adverse events
Secondary: change in trough FEV1, trough FVC, trough PEF from baseline to week
52, change in weekly mean morning and evening PEF and PEF variability, weekly mean
number of puffs of rescue medication use per day (change from baseline), weekly mean
score of asthma symptoms in the morning and during the day (5-point verbal rating
scale, with 1 representing no impairment)
Notes Funding: Boehringer Ingelheim with collaboration from Pfizer
ID number(s): NCT01340209; 205.464
Patients were allowed to continue taking maintenance medication, including LABA, but
we were unable to confirm how many did so. For this reason, the study was removed in
a sensitivity analysis from the primary outcomes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Eligible patients were randomised in
blocks, 2:2:1” with a “pseudo-random
number generator”
Allocation concealment (selection bias) Low risk “Randomisation was achieved via a third-
party phone- or web-based system involv-
ing a validated pseudo-random number
generator and a supplied seed number, us-
ing a block size of 5”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “In order to maintain the blind, patients in
the placebo group also used the Respimat
SoftMist inhaler, and the placebo inhala-
tion solution was identical in appearance to
the tiotropium inhalation solution. Blind-
ing was maintained until after database
lock.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above, all parties were blind until after
database lock.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Total dropout was less than 10% in all
groups. “Full analysis set: all patients of the
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treated set for which baseline and at least
1 post-baseline efficacy measurement were
available”. This was used for efficacy mea-
sures, and included at least 85% of the ran-
domised population
Selective reporting (reporting bias) Low risk Data for all pre-specified outcomes were
published or available in full on Clinical-
Trials.gov
Other bias Low risk None noted
ACQ: Asthma Control Questionnaire; AQLQ: Asthma Quality of Life Questionnaire; AUC:area under the curve; COPD: chronic ob-
structive pulmonary disease; FEV1 : forced expiratory volume in one second; FVC: forced vital capacity; ICS: inhaled corticosteroids;
ITT: intention-to-treat; LABA: long-acting beta2-agonists; NR: not reported;OCS: oral corticosteroids; PEF: peak expiratory flow;
RTI: respiratory tract infection; RCT: randomised controlled trial; SD: standard deviation; SGRQ: St George’s Respiratory Ques-
tionnaire; TB: tuberculosis.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
2009-018006-21 Participants not taking LABA/ICS combination and too short (4-week cross-over)
2010-018471-26 Participants not taking LABA/ICS combination and too short (4-week cross-over)
Bateman 2011 Participants not taking LABA/ICS combination
Beeh 2013 Participants not taking LABA/ICS combination, and too short
Dusser 2014 Not an RCT - meta-analysis
Fardon 2007 Participants not taking LABA/ICS combination, and too short
FitzGerald 2014 Not an RCT - meta-analysis
Haggart 2004 Participants not taking LABA/ICS combination
Haughney 2014 Not an RCT - meta-analysis
Jiang 2006 Wrong intervention - triple therapy of traditional Chinese medicine
Kerstjens 2011 Too short, 8 weeks
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Kerstjens 2015 Participants not taking LABA/ICS combination
Lee 2014 Participants not taking LABA/ICS combination
Lommatzsch 2014 Wrong design - cross-over with 4-week phases
Murphy 2014 Not an RCT - meta-analysis
NCT01573624 LAMA/ICS against LABA, not in combination as triple therapy
NCT02039011 Too short - 2-4 weeks
Paggiaro 2013 Participants not taking LABA/ICS combination
Peters 2010 Participants not taking LABA/ICS combination
Price 2014 Not an RCT - meta-analysis
Rajanandh 2014 Participants not taking LABA/ICS combination
Rajanandh 2015 Participants not taking LABA/ICS combination
Rodrigo 2015 Not an RCT - meta-analysis
Salvi 2009 Participants not taking LABA/ICS combination and too short
Timmer 2014 Too short
Vandewalker 2015 Adolescent study
Vogelberg 2014 Too short and study of adolescents not adults
Yoshida 2013 Comparison group with comorbid emphysema
Characteristics of ongoing studies [ordered by study ID]
NCT01696214
Trial name or title A pilot study to determine the feasibility and utility of implementing of the full scale TOM trial (SAPS)
Methods Allocation: randomised
Endpoint classification: efficacy study
Intervention model: factorial assignment
Masking: double-blind (subject, investigator)
Primary purpose: treatment
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Participants Estimated enrolment: 20
Inclusion criteria:
Males and females, aged 18-50; smoke ≥ 5 cigarettes per day for at least 5 years; positive urine cotinine test;
physician diagnosed asthma; symptomatic, as evidenced by use of SABA ≥ 2 times per week for relief of
asthma symptoms, or 1 or more nocturnal awakenings per week for asthma symptoms; pre-BD FEV1 ≥ 40%
predicted; asthma diagnosis confirmed by either albuterol reversibility of FEV1 by 12% or more, or 20% fall
in FEV1 at 8 mg or less of methacholine. If over age 45, a DLCO greater than 80% predicted; females of
childbearing potential: not pregnant, not lactating and agree to practice an adequate birth control method
(abstinence, combination barrier and spermicide, or hormonal) for the duration of the study
Exclusion criteria:
Diagnosis of COPD or emphysema; other major chronic illnesses in the opinion of the investigator that might
interfere with the study, including but not limited to uncontrolled diabetes, uncontrolled HIV infection
or other immune system disorder, hyperthyroidism, seizure disorders, renal failure, liver disease, non-skin
cancer, unstable psychiatric illness; recent active substance abuse (in past 6 months); lung disease other
than asthma including COPD, bronchiectasis, sarcoidosis, or other significant lung disease; unstable cardiac
disease (decompensated CHF, unstable angina, recent MI, atrial fibrillation, supraventricular or ventricular
tachycardia, congenital heart disease, or severe uncontrolled hypertension); high risk of near fatal or fatal
asthma as defined by the following: 1-3 ICU admission of asthma in the past year,more than 2 hospitalisations
for asthma in the previous year, more than 3 ED visits for asthma in the previous year, intubation or ICU
admission for asthma in the past 2 years, use of more than 2 canisters of inhaled SABAs in past month; acute
asthma exacerbation in the past 4 weeks (treatment with systemic corticosteroids)
Interventions For this review, the comparison between group 1 and group 4 meets the inclusion criteria:
1. Advair 250/50, placebo, placebo, placebo
2. Advair 100/50 and LTRA, placebo, placebo
3. Advair 100/50 and Theo, placebo, placebo
4. Advair 100/50 and tiotropium, placebo, placebo
Outcomes Primary outcome: Asthma Control Test
Secondary outcomes: Asthma Symptom Utility Index (AUSI), FEV1, FVC, FEV1/FVC ratio
Starting date First received: June 25, 2012
Last updated: June 11, 2013
Last verified: June 2013
Study start date: October 2012
Estimated study completion date: September 2016
Estimated primary completion date: September 2014 (final data collection date for primary outcomemeasure)
Contact information Airway Researchj & Clinical Trials Center
San Diego, California, United States, 92103
Contact: Paul Ferguson pferguson@ucsd.edu
Principal investigator: Joe Ramsdell, MD
Notes ID number(s): ARCTC-09 and IR34HL109482-01A1
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BD: bronchodilator; COPD: chronic obstructive pulmonary disorder; CHF: congestive heart failure;DLCO: diffusing capacity of the
lungs for carbon monoxide; ED: emergency department: FEV1 : forced expiratory volume in one second; FVC: forced vital capacity;
ICU: intensive care unit; LTRA: leukotriene receptor antagonist; MI: myocardial infarction; SABA: short-acting beta2-agonists.
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D A T A A N D A N A L Y S E S
Comparison 1. LAMA + LABA/ICS vs LABA/ICS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Exacerbations requiring oral
corticosteroids (patients with at
least one)
2 907 Odds Ratio (M-H, Random, 95% CI) 0.76 [0.57, 1.02]
2 Exacerbations requiring oral
corticosteroids (number per
patient)
2 907 Rate Ratio (Random, 95% CI) 0.79 [0.53, 1.17]
3 Time to first exacerbation
requiring oral corticosteroids
2 907 Hazard Ratio (Random, 95% CI) 0.80 [0.63, 1.01]
4 Quality of life (AQLQ) 2 907 Mean Difference (IV, Random, 95% CI) 0.09 [-0.03, 0.20]
5 Serious adverse events 3 1197 Odds Ratio (M-H, Random, 95% CI) 0.60 [0.24, 1.47]
6 Exacerbations requiring hospital
admission
3 1191 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.04, 0.01]
7 Lung function (change in trough
FEV1 L)
3 1191 Mean Difference (IV, Random, 95% CI) 0.07 [0.03, 0.11]
8 Lung function (change in trough
FVC)
3 1191 Mean Difference (IV, Random, 95% CI) 0.07 [0.02, 0.13]
9 Asthma control (ACQ) 2 907 Mean Difference (IV, Random, 95% CI) -0.13 [-0.23, -0.02]
10 Asthma control (ACQ
responder)
2 1192 Odds Ratio (M-H, Random, 95% CI) 1.42 [0.88, 2.29]
11 Any adverse events 3 1197 Odds Ratio (M-H, Random, 95% CI) 0.70 [0.52, 0.94]
12 Quality of life (AQLQ) by
timeframe
2 Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 24-26 weeks 2 907 Mean Difference (IV, Random, 95% CI) 0.11 [-0.03, 0.24]
12.2 48-52 weeks 2 907 Mean Difference (IV, Random, 95% CI) 0.09 [-0.03, 0.20]
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Analysis 1.1. Comparison 1 LAMA + LABA/ICS vs LABA/ICS, Outcome 1 Exacerbations requiring oral
corticosteroids (patients with at least one).
Review: Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for
adults with asthma
Comparison: 1 LAMA + LABA/ICS vs LABA/ICS
Outcome: 1 Exacerbations requiring oral corticosteroids (patients with at least one)
Study or subgroup LAMA + LABA/ICS LABA/ICS alone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kerstjens 2012a (1) 53/237 68/222 47.0 % 0.65 [ 0.43, 0.99 ]
Kerstjens 2012b 69/216 81/232 53.0 % 0.88 [ 0.59, 1.30 ]
Total (95% CI) 453 454 100.0 % 0.76 [ 0.57, 1.02 ]
Total events: 122 (LAMA + LABA/ICS), 149 (LABA/ICS alone)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.01, df = 1 (P = 0.32); I2 =1%
Test for overall effect: Z = 1.85 (P = 0.064)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours LAMA + LABA/ICS Favours LABA/ICS alone
(1) In both trials, ’severe’ exacerbations were defined as
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Analysis 1.2. Comparison 1 LAMA + LABA/ICS vs LABA/ICS, Outcome 2 Exacerbations requiring oral
corticosteroids (number per patient).
Review: Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for
adults with asthma
Comparison: 1 LAMA + LABA/ICS vs LABA/ICS
Outcome: 2 Exacerbations requiring oral corticosteroids (number per patient)
Study or subgroup LAMA + LABA/ICS LABA/ICS alone log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Kerstjens 2012a 237 222 -0.4463 (0.1625) 49.2 % 0.64 [ 0.47, 0.88 ]
Kerstjens 2012b 216 232 -0.0408 (0.1547) 50.8 % 0.96 [ 0.71, 1.30 ]
Total (95% CI) 453 454 100.0 % 0.79 [ 0.53, 1.17 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 3.27, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 1.19 (P = 0.24)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours LAMA + LABA/ICS FavoursLABA/ICS alone
Analysis 1.3. Comparison 1 LAMA + LABA/ICS vs LABA/ICS, Outcome 3 Time to first exacerbation
requiring oral corticosteroids.
Review: Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for
adults with asthma
Comparison: 1 LAMA + LABA/ICS vs LABA/ICS
Outcome: 3 Time to first exacerbation requiring oral corticosteroids
Study or subgroup LAMA + LABA/ICS LABA/ICS alone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Kerstjens 2012a 237 222 -0.3567 (0.182) 45.1 % 0.70 [ 0.49, 1.00 ]
Kerstjens 2012b 216 232 -0.1165 (0.1651) 54.9 % 0.89 [ 0.64, 1.23 ]
Total (95% CI) 453 454 100.0 % 0.80 [ 0.63, 1.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.066)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours LAMA + LABA/ICS FavoursLABA/ICS alone
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Analysis 1.4. Comparison 1 LAMA + LABA/ICS vs LABA/ICS, Outcome 4 Quality of life (AQLQ).
Review: Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for
adults with asthma
Comparison: 1 LAMA + LABA/ICS vs LABA/ICS
Outcome: 4 Quality of life (AQLQ)
Study or subgroup LAMA + LABA/ICS LABA/ICS alone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kerstjens 2012a 237 5.147 (0.8929) 222 5.11 (0.894) 51.7 % 0.04 [ -0.13, 0.20 ]
Kerstjens 2012b 216 5.085 (0.9112) 232 4.95 (0.9139) 48.3 % 0.14 [ -0.03, 0.31 ]
Total (95% CI) 453 454 100.0 % 0.09 [ -0.03, 0.20 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.72, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.15)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours LABA/ICS alone Favours LAMA + LABA/ICS
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Analysis 1.5. Comparison 1 LAMA + LABA/ICS vs LABA/ICS, Outcome 5 Serious adverse events.
Review: Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for
adults with asthma
Comparison: 1 LAMA + LABA/ICS vs LABA/ICS
Outcome: 5 Serious adverse events
Study or subgroup LAMA + LABA/ICS LABA/ICS alone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kerstjens 2012a 18/237 15/222 34.8 % 1.13 [ 0.56, 2.31 ]
Kerstjens 2012b 19/219 25/234 36.6 % 0.79 [ 0.42, 1.49 ]
Ohta 2014 (1) 8/228 9/57 28.6 % 0.19 [ 0.07, 0.53 ]
Total (95% CI) 684 513 100.0 % 0.60 [ 0.24, 1.47 ]
Total events: 45 (LAMA + LABA/ICS), 49 (LABA/ICS alone)
Heterogeneity: Tau2 = 0.47; Chi2 = 8.25, df = 2 (P = 0.02); I2 =76%
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours LAMA + LABA/ICS Favours LABA/ICS alone
(1) 2.5 mcg and 5 mcg intervention groups combined. Four events occurred in both dose groups.
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Analysis 1.6. Comparison 1 LAMA + LABA/ICS vs LABA/ICS, Outcome 6 Exacerbations requiring hospital
admission.
Review: Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for
adults with asthma
Comparison: 1 LAMA + LABA/ICS vs LABA/ICS
Outcome: 6 Exacerbations requiring hospital admission
Study or subgroup LAMA + LABA/ICS LABA/ICS alone
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kerstjens 2012a 8/237 10/222 40.2 % -0.01 [ -0.05, 0.02 ]
Kerstjens 2012b 8/216 10/232 38.8 % -0.01 [ -0.04, 0.03 ]
Ohta 2014 (1) 1/228 2/56 21.0 % -0.03 [ -0.08, 0.02 ]
Total (95% CI) 681 510 100.0 % -0.01 [ -0.04, 0.01 ]
Total events: 17 (LAMA + LABA/ICS), 22 (LABA/ICS alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.68, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
-0.1 -0.05 0 0.05 0.1
Favours LAMA + LABA/ICS Favours LABA/ICS alone
(1) 2.5 mcg and 5 mcg intervention groups combined
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Analysis 1.7. Comparison 1 LAMA + LABA/ICS vs LABA/ICS, Outcome 7 Lung function (change in trough
FEV1 L).
Review: Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for
adults with asthma
Comparison: 1 LAMA + LABA/ICS vs LABA/ICS
Outcome: 7 Lung function (change in trough FEV1 L)
Study or subgroup LAMA + LABA/ICS LABA/ICS alone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kerstjens 2012a 237 0.129 (0.3849) 222 0.09 (0.3725) 35.2 % 0.04 [ -0.03, 0.11 ]
Kerstjens 2012b 216 0.155 (0.338) 232 0.06 (0.3503) 41.6 % 0.09 [ 0.03, 0.16 ]
Ohta 2014 (1) 228 0.137 (0.292) 56 0.08 (0.2918) 23.2 % 0.06 [ -0.02, 0.15 ]
Total (95% CI) 681 510 100.0 % 0.07 [ 0.03, 0.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.10, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.22 (P = 0.0013)
Test for subgroup differences: Not applicable
-0.2 -0.1 0 0.1 0.2
Favours LABA/ICS alone Favours LAMA + LABA/ICS
(1) 2.5 mcg and 5 mcg intervention groups combined
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Analysis 1.8. Comparison 1 LAMA + LABA/ICS vs LABA/ICS, Outcome 8 Lung function (change in trough
FVC).
Review: Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for
adults with asthma
Comparison: 1 LAMA + LABA/ICS vs LABA/ICS
Outcome: 8 Lung function (change in trough FVC)
Study or subgroup LAMA + LABA/ICS LABA/ICS alone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kerstjens 2012a 237 0.173 (0.4772) 222 0.06 (0.4768) 35.4 % 0.11 [ 0.02, 0.20 ]
Kerstjens 2012b 216 0.142 (0.4703) 232 0.07 (0.4722) 35.4 % 0.07 [ -0.02, 0.16 ]
Ohta 2014 (1) 228 0.1445 (0.3299) 56 0.11 (0.3293) 29.1 % 0.03 [ -0.06, 0.13 ]
Total (95% CI) 681 510 100.0 % 0.07 [ 0.02, 0.13 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.41, df = 2 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 2.78 (P = 0.0055)
Test for subgroup differences: Not applicable
-0.2 -0.1 0 0.1 0.2
Favours LABA/ICS alone Favours LAMA + LABA/ICS
(1) 2.5 mcg and 5 mcg intervention groups combined
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Analysis 1.9. Comparison 1 LAMA + LABA/ICS vs LABA/ICS, Outcome 9 Asthma control (ACQ).
Review: Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for
adults with asthma
Comparison: 1 LAMA + LABA/ICS vs LABA/ICS
Outcome: 9 Asthma control (ACQ)
Study or subgroup LAMA + LABA/ICS LABA/ICS alone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kerstjens 2012a 237 1.986 (0.8005) 222 2.11 (0.8046) 49.0 % -0.12 [ -0.27, 0.03 ]
Kerstjens 2012b 216 2.027 (0.7789) 232 2.16 (0.7768) 51.0 % -0.13 [ -0.28, 0.01 ]
Total (95% CI) 453 454 100.0 % -0.13 [ -0.23, -0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 2.41 (P = 0.016)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours LAMA + LABA/ICS Favours LABA/ICS alone
Analysis 1.10. Comparison 1 LAMA + LABA/ICS vs LABA/ICS, Outcome 10 Asthma control (ACQ
responder).
Review: Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for
adults with asthma
Comparison: 1 LAMA + LABA/ICS vs LABA/ICS
Outcome: 10 Asthma control (ACQ responder)
Study or subgroup LAMA + LABA/ICS LABA/ICS alone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kerstjens 2012a (1) 263/453 205/454 67.6 % 1.68 [ 1.29, 2.19 ]
Ohta 2014 (2) 168/228 42/57 32.4 % 1.00 [ 0.52, 1.93 ]
Total (95% CI) 681 511 100.0 % 1.42 [ 0.88, 2.29 ]
Total events: 431 (LAMA + LABA/ICS), 247 (LABA/ICS alone)
Heterogeneity: Tau2 = 0.07; Chi2 = 2.06, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours LABA/ICS alone Favours LAMA + LABA/ICS
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(1) Data presented here are pooled data for NCT00772538 and NCT00776984. Data were not available for each trial separately so had to be entered as one row.
(2) 2.5 mcg and 5 mcg intervention groups combined
Analysis 1.11. Comparison 1 LAMA + LABA/ICS vs LABA/ICS, Outcome 11 Any adverse events.
Review: Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for
adults with asthma
Comparison: 1 LAMA + LABA/ICS vs LABA/ICS
Outcome: 11 Any adverse events
Study or subgroup LAMA + LABA/ICS LABA/ICS alone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kerstjens 2012a (1) 167/237 170/222 50.1 % 0.73 [ 0.48, 1.11 ]
Kerstjens 2012b (2) 168/219 196/234 39.9 % 0.64 [ 0.40, 1.02 ]
Ohta 2014 (3) 200/228 51/57 10.0 % 0.84 [ 0.33, 2.14 ]
Total (95% CI) 684 513 100.0 % 0.70 [ 0.52, 0.94 ]
Total events: 535 (LAMA + LABA/ICS), 417 (LABA/ICS alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours LAMA + LABA/ICS Favours LABA/ICS alone
(1) The listed events were reported in at least 2% of patients who underwent randomisation
(2) The listed events were reported in at least 2% of patients who underwent randomisation
(3) 2.5 mcg and 5 mcg intervention groups combined
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Analysis 1.12. Comparison 1 LAMA + LABA/ICS vs LABA/ICS, Outcome 12 Quality of life (AQLQ) by
timeframe.
Review: Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for
adults with asthma
Comparison: 1 LAMA + LABA/ICS vs LABA/ICS
Outcome: 12 Quality of life (AQLQ) by timeframe
Study or subgroup LAMA + LABA/ICS LABA/ICS alone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 24-26 weeks
Kerstjens 2012a 237 5.125 (0.8775) 222 5.08 (0.8791) 50.9 % 0.04 [ -0.12, 0.20 ]
Kerstjens 2012b 216 5.047 (0.8965) 232 4.87 (0.8834) 49.1 % 0.18 [ 0.01, 0.34 ]
Subtotal (95% CI) 453 454 100.0 % 0.11 [ -0.03, 0.24 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.36, df = 1 (P = 0.24); I2 =26%
Test for overall effect: Z = 1.58 (P = 0.11)
2 48-52 weeks
Kerstjens 2012a 237 5.147 (0.8929) 222 5.11 (0.894) 51.7 % 0.04 [ -0.13, 0.20 ]
Kerstjens 2012b 216 5.085 (0.9112) 232 4.95 (0.9139) 48.3 % 0.14 [ -0.03, 0.31 ]
Subtotal (95% CI) 453 454 100.0 % 0.09 [ -0.03, 0.20 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.72, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.15)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
-0.5 -0.25 0 0.25 0.5
Favours LABA/ICS alone Favours LAMA + LABA/ICS
A D D I T I O N A L T A B L E S
Table 1. Summary of included studies
Study ID Country Total N Weeks Design LABA/ICS
background
LAMA add-
on
Age (years) % FEV1
Kerstjens
2012a
Interna-
tional
459 48 P, R, DB/DD Sta-
ble high dose
LABA/ICS
Tiotropium
(Respimat) 5
µg
53.4 54.6
Kerstjens
2012b
Interna-
tional
453 48 P, R, DB/DD Sta-
ble high dose
LABA/ICS
Tiotropium
(Respimat) 5
µg
52.5 55.0
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Table 1. Summary of included studies (Continued)
Ohta 2014 Japan 285 52 P, R, DB/DD Medium ICS
+/- LABA
Tiotropium
(Respimat) 2.
5/5 µg
44.5 NR
NCT02127697
Interna-
tional
Withdrawn 52 P, R, DB/DD Any stable
dose LABA/
ICS
Glycopyrro-
nium
NA NA
DB/DD: double-blind, double-dummy; % FEV1 : forced expiratory volume in 1 second, percentage of the predicted normal value;
LABA/ICS: inhaled corticosteroids/long-acting-beta2-agonist combination; NA: not applicable;NR: not reported; P: parallel; R:
randomised
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL Monthly
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
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Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
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8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Adrenal Cortex Hormones
#6 inhal* NEAR (corticosteroid* or steroid* or glucocorticoid*)
#7 beclomethasone* or beclometasone* OR triamcinolone* OR fluticasone* OR budesonide* OR betamethasone* OR flunisolide*
OR ciclesonide* OR mometasone*
#8 ICS:TI,AB
#9 #5 or #6 or #7 or #8
#10 MeSH DESCRIPTOR Adrenergic beta-Agonists
#11 long* NEAR beta* NEAR agonist*
#12 LABA:TI,AB
#13 *formoterol
#14 salmeterol
#15 vilanterol
#16 #10 or #11 or #12 or #13 or #14 or #15
#17 Muscarinic* NEXT Antagonist*
#18 LAMA:TI,AB
#19 Glycopyrronium*
#20 NVA237
#21 Seebri OR Breezhaler
#22 Aclidinium*
#23 LAS34273
#24 Turdorza or Pressair or Eklira or Genuair
#25 tiotropium*
#26 Spiriva
#27 umeclidinium*
#28 GSK573719
#29 #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28
#30 #9 AND #16 and #29
#31 triple* NEAR2 therap*
#32 #4 AND (#30 OR #31)
[Note: in search line #1, MISC1 denotes the filed in which the reference has been coded for condition, in this case, asthma]
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We did not anticipate that a study would include only a subset of participants that met the inclusion criteria relating to background
medication, and so we did not outline methods to guide how to deal with Ohta 2014. We chose to include the study and describe
sensitivity analyses without it where there was heterogeneity in the analyses. We also factored in the partly indirect population in the
GRADE ratings for outcomes to which the study contributed data.
We were unable to conduct appropriate subgroup analyses to investigate the potential effect of duration of therapy, dose and type of
LABA/ICS and dose and type of LAMA due to the small number of studies included. Where possible, we conducted subgroup analyses
by looking at dose groups within multi-arm studies and splitting the placebo group accordingly.
We were also unable to test the robustness of the analyses by performing sensitivity analyses on the basis of risk of performance bias,
although this was because we rated all of the included studies as having a low risk for this domain. We did not include any unpublished
data in the analyses and found no cross-over studies, so these sensitivity analyses were also not possible.
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